Ginkgo Bioworks Buys Reverie Labs To Advance AI-driven Drug discovery

Photo:Representative image

Ginkgo Bioworks, a startup developing the leading platform for cell programming and biosecurity, has announced the purchase of key assets from Reverie Labs, which created and applied AI/ML techniques to expedite drug discovery. Ginkgo has purchased Reverie's infrastructure and software for training large-scale AI foundation models, and four key members of Reverie's artificial intelligence (AI) team will join Ginkgo Bioworks. 

The acquisition is designed to boost Ginkgo's AI/ML-driven discovery services offering while also accelerating Ginkgo's efforts to develop next-generation biological foundation models.

Anna Marie Wagner, SVP, head of corporate development and head of AI of Ginkgo Bioworks: "The Reverie Labs team has built an impressive platform and architecture for computationally-driven biological discovery and validation, and it's going to be very exciting to be able to use the tools they've developed across the wide, diverse range of discovery challenges our customers face. It has been a joy to work with this team throughout the transaction, and I'm looking forward to working with the Reverie team to accelerate the development of multimodal foundation models at Ginkgo."

The Reverie group joining Ginkgo as a piece of this exchange (counting Reverie's CTO, Ankit Gupta, who will join Ginkgo as head of simulated intelligence/ML progression) will uphold both the onboarding of Dream's innovation into Ginkgo's developing AI/ML framework and furthermore support the future turn of events and utilization of AI based strategies to design biology.

Ginkgo, a biotech firm will consolidate Reverie's models, programming, and work processes to propel its framework for AI/ML/-driven exploratory plan. Reverie's generative AI stage for science will likewise be added into Ginkgo's capacities to help little atom programs.